Respirology最新文献_第7页

Association Between the Visceral Fat-to-Muscle Ratio and Severe Exacerbation of COPD: A Prospective Cohort Study.

IF 6.6 2区医学

Respirology Pub Date : 2025-02-09 DOI: 10.1111/resp.14883

Yuanyuan Li, Lu Wang, Zhen Li, Tao Luo, Qi Sun, Henry S Lynn, Jianghong Dai

{"title":"Association Between the Visceral Fat-to-Muscle Ratio and Severe Exacerbation of COPD: A Prospective Cohort Study.","authors":"Yuanyuan Li, Lu Wang, Zhen Li, Tao Luo, Qi Sun, Henry S Lynn, Jianghong Dai","doi":"10.1111/resp.14883","DOIUrl":"https://doi.org/10.1111/resp.14883","url":null,"abstract":"Background and objective: An imbalanced fat and muscle mass ratio might impact exacerbation of chronic obstructive pulmonary disease (COPD). We investigated the association of visceral fat-to-muscle ratio (VMR) with severe COPD exacerbation requiring hospitalisation.Methods: This prospective cohort study in COPD patients was performed along with the Xinjiang Multi-Ethnic Cohort study between May 2018 and December 2023. Baseline VMR was calculated from visceral fat area and muscle mass measured by bioelectrical impedance analysis. Numbers of COPD exacerbation hospitalizations were monitored. Associations between various variables and exacerbation were assessed by logistics regression and Zero-inflated Poisson regression analyses.Results: A total of 631 COPD patients were included, with 186 (29.48%) and 304 (48.18%) severe COPD exacerbation within 1 and 5 years, respectively. Compared with body mass index and other obesity indicators, VMR had stronger associations with severe exacerbation. A higher VMR was associated with increased risks of 1-year and 5-year exacerbation (odds ratio [OR] = 1.34 and 1.44, respectively). The subgroup female and overweight individuals showed a strong association (female OR = 1.89 and 1.99, overweight OR = 1.80 and 1.88, for 1 and 5-year exacerbation, respectively). The number of COPD exacerbation increased by 46% for each one-point VMR increase. These results remained unchanged in the sensitivity analyses after removing underweight patients or smoke influence, as well as in the competing risk analysis when considering other causes for death.Conclusion: VMR was a risk factors of severe COPD exacerbation. Proactive assessment of VMR might be helpful to guide management of COPD patients.","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pre-Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients.

IF 6.6 2区医学

Respirology Pub Date : 2025-02-07 DOI: 10.1111/resp.14894

Roger M Li, Dino B A Tan, Chantalia Tedja, Wendy A Cooper, Helen E Jo, Christopher Grainge, Ian N Glaspole, Nicole Goh, Samantha Ellis, Peter M A Hopkins, Christopher Zappala, Gregory J Keir, Paul N Reynolds, Sally Chapman, E Haydn Walters, Darryl Knight, Svetlana Baltic, HuiJun Chih, Tamera J Corte, Yuben P Moodley

{"title":"Pre-Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients.","authors":"Roger M Li, Dino B A Tan, Chantalia Tedja, Wendy A Cooper, Helen E Jo, Christopher Grainge, Ian N Glaspole, Nicole Goh, Samantha Ellis, Peter M A Hopkins, Christopher Zappala, Gregory J Keir, Paul N Reynolds, Sally Chapman, E Haydn Walters, Darryl Knight, Svetlana Baltic, HuiJun Chih, Tamera J Corte, Yuben P Moodley","doi":"10.1111/resp.14894","DOIUrl":"https://doi.org/10.1111/resp.14894","url":null,"abstract":"Background and objective: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a poor prognosis. Antifibrotics slow the decline of pulmonary function after 12-months, but limited studies have examined the role of circulatory biomarkers in antifibrotic treated IPF patients.Methods: Serum from 98 IPF participants, from the Australian Idiopathic Pulmonary Fibrosis Registry were collected at four time-points over 1 year post-antifibrotic treatment and analysed as two separate cohorts. Patients were stratified as progressive, if they experienced ≥ 10% decline in FVC or ≥ 15% decline in DLCO or were deceased within 1 year of treatment initiation: or otherwise as stable. Ten molecules of interest were measured by ELISAs in patient serum.Results: Baseline MMP7 levels were higher in progressive than stable patients in Cohort 1 (p = 0.02) and Cohort 2 (p = 0.0002). Baseline MMP7 levels also best differentiated progressive from stable patients (Cohort 1, AUC = 0.74, p = 0.02; Cohort 2, AUC = 0.81, p = 0.0003). Regression analysis of the combined cohort showed that elevated MMP7 levels predicted 12-month progression (OR = 1.530, p = 0.010) and increased risk of overall mortality (HR = 1.268, p = 0.002). LASSO regression identified a multi-biomarker panel (MMP7, ICAM-1, CHI3L1, CA125) that differentiated progression more accurately than MMP7 alone. Furthermore, GAP combined with MMP7, ICAM-1, CCL18 and SP-D was more predictive of 3-year mortality than GAP alone.Conclusion: MMP7 along with a multi-biomarker and GAP panel can predict IPF progression and mortality, with the potential for optimising management.","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143371005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dynapenia and Sarcopenia as Risk Factors for Mortality in Interstitial Lung Disease. 作为间质性肺病死亡率风险因素的动力性减少症和肌少症

IF 6.6 2区医学

Respirology Pub Date : 2025-02-04 DOI: 10.1111/resp.14892

Alan Aldair Ibarra-Fernández, Robinson Robles-Hernández, Arturo Orea-Tejeda, Dulce González-Islas, Angelia Jiménez-Valentín, Rocío Sánchez-Santillán, Laura Patricia Arcos-Pacheco, Emilio Gutiérrez-Luna, Andrea Zurita-Sandoval, Tomas Peña-Espinosa, Rosaura Gutiérrez-Vargas, Laura Flores-Cisneros

{"title":"Dynapenia and Sarcopenia as Risk Factors for Mortality in Interstitial Lung Disease.","authors":"Alan Aldair Ibarra-Fernández, Robinson Robles-Hernández, Arturo Orea-Tejeda, Dulce González-Islas, Angelia Jiménez-Valentín, Rocío Sánchez-Santillán, Laura Patricia Arcos-Pacheco, Emilio Gutiérrez-Luna, Andrea Zurita-Sandoval, Tomas Peña-Espinosa, Rosaura Gutiérrez-Vargas, Laura Flores-Cisneros","doi":"10.1111/resp.14892","DOIUrl":"https://doi.org/10.1111/resp.14892","url":null,"abstract":"Background and objective: Fibrotic interstitial lung disease (ILD) is associated with high morbidity and mortality. Patients often exhibit impaired nutritional status and alterations in body composition, such as dynapenia and sarcopenia, which correlate with poor pulmonary function, reduced exercise tolerance and diminished quality of life. However, the impact of dynapenia and sarcopenia on prognosis has not been examined extensively in ILD patients. We assessed the impact of dynapenia and sarcopenia as risk factors for mortality and their prevalence in ILD.Methods: Prospective cohort study. ILD was classified into idiopathic pulmonary fibrosis (IPF), connective tissue disease-related ILD (CTD-ILD) and chronic hypersensitivity pneumonitis (CHP). Patients over 18 years old with a confirmed diagnosis of ILD were included, while those with diagnoses of cancer, human immunodeficiency virus and neurological disease were excluded. Dynapenia and sarcopenia were determined according to EWGSOP2 criteria.Results: Ninety-eight ILD patients were included; 33.66% had IPF, 47.96% had CTD-ILD, and 18.37% had CHP. The mean age was 63.89 ± 12.02 years; 37.76% were male. The risk factors associated with mortality included dynapenia (HR: 2.04, 95% CI: 1.10-3.77, p = 0.022), sarcopenia (HR: 1.88, 95% CI; 1.00-3.33, p = 0.049) and exercise tolerance (HR: 0.99, 95% CI; 0.99-0.99, p = 0.023), adjusted for confounding variables. The prevalence of dynapenia was 45% in ILD; 51% in IPF, 35% in CTD-ILD and 61% in CHP. The prevalence of sarcopenia was 29%; both IPF (39%) and CHP (50%) had a higher prevalence of sarcopenia than CTD-ILD (14%).Conclusion: Sarcopenia and dynapenia are independent risk factors for mortality in ILD.","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Allele-specific micro-RNA-mediated regulation of ADAM33 in childhood allergic asthma. 等位基因特异性微 RNA 介导的 ADAM33 在儿童过敏性哮喘中的调控。

IF 6.6 2区医学

Respirology Pub Date : 2025-02-01 Epub Date: 2024-10-30 DOI: 10.1111/resp.14846

Xiang Wen, Juan Zhou, Heping Fang, Juan Li, Run Wang, Dan Zeng, Xiaohong Xie, Yu Deng, Luo Ren, Enmei Liu

{"title":"Allele-specific micro-RNA-mediated regulation of ADAM33 in childhood allergic asthma.","authors":"Xiang Wen, Juan Zhou, Heping Fang, Juan Li, Run Wang, Dan Zeng, Xiaohong Xie, Yu Deng, Luo Ren, Enmei Liu","doi":"10.1111/resp.14846","DOIUrl":"10.1111/resp.14846","url":null,"abstract":"Background and objective: A disintegrin and metalloprotease 33 (ADAM33) is associated with asthma susceptibility, and its genetic variations impact susceptibility and disease severity. However, the mechanisms remain unclear. This study aimed to investigate ADAM33 single nucleotide polymorphisms (SNPs) in childhood asthma susceptibility and explore their regulatory mechanisms.Methods: Eleven selected SNPs in ADAM33 were genotyped and identified the association with asthma susceptibility. In the validation cohort, we measured plasma sADAM33 levels and compared them with disease severity among children with different SNP genotypes. Computational predictions identified miRNAs targeting the SNP, and the impact of the SNP on miRNA regulation was confirmed using a dual luciferase reporter system. Finally, we validated the regulatory role of miRNAs on ADAM33 expression using an in vitro model with upregulated ADAM33 expression.Results: Only rs3918400 was associated with asthma susceptibility. In the validation cohort, children with allergic asthma exhibited higher plasma sADAM33 levels. Among asthmatic children, those with the rs3918400 CT/TT genotype had higher sADAM33 levels, poorer asthma control, more severe airway hyper-responsiveness, lower FEV1% and higher dust mite-specific IgE activity compared to those with the CC genotype. miR-3928-5p bound strongly to the rs3918400 C allele and effectively reduced ADAM33 protein expression in CC genotype cells. However, the binding affinity of miR-3928-5p to the T allele was weaker, resulting in diminished negative regulation of protein expression.Conclusion: The rs3918400 SNP affects the negative regulation of ADAM33 by miR-3928-5p, potentially participating in a complex interplay of processes related to childhood asthma susceptibility.","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"113-123"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pulmonary function testing in COPD: Anchoring clinical relevance. 慢性阻塞性肺病肺功能检测：锚定临床相关性。

IF 6.6 2区医学

Respirology Pub Date : 2025-02-01 Epub Date: 2024-12-08 DOI: 10.1111/resp.14867

Bruce R Thompson

引用次数: 0

Lung Cancer in Non-Smokers. 非吸烟者的肺癌。

IF 6.6 2区医学

Respirology Pub Date : 2025-02-01 Epub Date: 2025-01-13 DOI: 10.1111/resp.14879

Akihiko Miyanaga, Masahiro Seike

引用次数: 0

Leading Women in Respiratory Care: Letter From Saudi Arabia.

IF 6.6 2区医学

Respirology Pub Date : 2025-02-01 Epub Date: 2025-01-27 DOI: 10.1111/resp.14881

Fatma Almaghlouth, Amal Alamer

引用次数: 0

Usability of a smartphone application for patients with interstitial lung disease: Results from the Registry for Better Understanding of ILD (RE-BUILD) pilot study. 用于间质性肺病患者的智能手机应用程序的可用性：来自更好地了解ILD注册（RE-BUILD）试点研究的结果。

IF 6.6 2区医学

Respirology Pub Date : 2025-02-01 Epub Date: 2024-12-17 DOI: 10.1111/resp.14874

Laura M Glenn, Dan Jackson, Carly Barton, Doris Lan, Lisa Fuhrmeister, Karen Symons, Louise Turnour, Ben Tefay, Anne E Holland, Nicole S L Goh, Lauren K Troy, Mark Brooke, Ian N Glaspole, Tamera J Corte

{"title":"Usability of a smartphone application for patients with interstitial lung disease: Results from the Registry for Better Understanding of ILD (RE-BUILD) pilot study.","authors":"Laura M Glenn, Dan Jackson, Carly Barton, Doris Lan, Lisa Fuhrmeister, Karen Symons, Louise Turnour, Ben Tefay, Anne E Holland, Nicole S L Goh, Lauren K Troy, Mark Brooke, Ian N Glaspole, Tamera J Corte","doi":"10.1111/resp.14874","DOIUrl":"10.1111/resp.14874","url":null,"abstract":"Background and objective: Digital technologies offer opportunities for remote monitoring, increased patient engagement and incorporation of patient-reported outcome measures (PROMs) into interstitial lung disease (ILD) care and research. This study evaluated the usability and patient experience of the RE-BUILD (Registry for Better Understanding of ILD) application, an ILD-specific smartphone app.Methods: Patients with ILD aged ≥18 years were recruited from three tertiary ILD centres to use the RE-BUILD app for 6 months. The mHealth App Usability Questionnaire (MAUQ) was evaluated at 1, 3 and 6 months and patients received monthly prompts to enter clinical and PROM data. Qualitative interviews regarding patient experience were performed in a subset of 10.Results: Fifty patients, with mean age 66.9 ± 10.3 years, 25 (50%) female were included. Participants used the app for a median of 48 (IQR 21-178.3) sessions, equivalent to 8 sessions (IQR 3.5-29.71) per month. Median number of days that the app was accessed was 37 (IQR 14-96.8), with 13 (26%) patients using the app >30 times per month. The most accessed app feature was physical activity, followed by 'air quality'. Participants agreed or strongly agreed that the app was easy to use (76.0%) easy to learn to use (79.8%) and well-organized with accessible information (74.8%). The median overall MAUQ score for usability was 5.69 (IQR 5.03-6.19). There was also a high rate of engagement with app functionalities.Conclusion: RE-BUILD is a usable and intuitive platform for self-monitoring and data collection in ILD. Patients report a high degree of satisfaction and have provided valuable feedback for its further development.","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"147-157"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Environmental impact of inhaled medicines: A Thoracic Society of Australia and New Zealand position statement. 吸入药物对环境的影响：澳大利亚和新西兰胸腔协会立场声明。

IF 6.6 2区医学

Respirology Pub Date : 2025-02-01 Epub Date: 2024-11-13 DOI: 10.1111/resp.14852

Danielle F Wurzel, Brett D Montgomery, Natalie Anderson, Elena K Schneider-Futschik, Johnson George, Sinthia Bosnic-Anticevich, Emily Stone, Robert J Hancox, James Fingleton, Stephanie Kuek, Helen Tope, John Blakey

{"title":"Environmental impact of inhaled medicines: A Thoracic Society of Australia and New Zealand position statement.","authors":"Danielle F Wurzel, Brett D Montgomery, Natalie Anderson, Elena K Schneider-Futschik, Johnson George, Sinthia Bosnic-Anticevich, Emily Stone, Robert J Hancox, James Fingleton, Stephanie Kuek, Helen Tope, John Blakey","doi":"10.1111/resp.14852","DOIUrl":"10.1111/resp.14852","url":null,"abstract":"Globally, more than 1.2 billion inhalers are purchased for asthma and chronic obstructive pulmonary disease (COPD) annually. In Australia and New Zealand, pressurized metered dose inhalers (pMDIs) are the leading delivery device prescribed and pMDI salbutamol can be purchased over the counter in Australia. These inhalers are a major contributor to healthcare related greenhouse gases. This is due to the propellants that they currently contain which have extremely high global warming potential (GWP). In this position paper, we report the findings of a Thoracic Society of Australia and New Zealand (TSANZ) working group on the environmental impact of inhaled respiratory medicines. We reviewed the use of inhaled medicines in Australia and New Zealand and their contribution to climate change and other environmental degradation. We propose strategies for health professionals and consumers to reduce environmental impact in the management of airway diseases. These include accurate diagnosis to avoid unnecessary treatment, better disease control to minimize the need for reliever therapy and actively choosing inhaler devices with lower environmental impacts when clinically appropriate. Inhaler selection should be tailored to the individual, aiming to achieve the best possible clinical outcome. Choosing an appropriate inhaler for an individual involves consideration of factors such as dexterity, inspiratory capacity and cost. In our current climate emergency and with the availability of lower carbon alternatives, health professionals should also consider environmental impact.","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"101-112"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142627009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reassessing pyrazinamide: Disentangling the myth of dose-dependent hepatotoxicity and advancing dosing strategies in elderly tuberculosis patients. 重新评估吡嗪酰胺：打破剂量依赖性肝毒性的神话，改进老年肺结核患者的用药策略。

IF 6.6 2区医学

Respirology Pub Date : 2025-02-01 Epub Date: 2024-12-17 DOI: 10.1111/resp.14872

Samadhi Patamatamkul

引用次数: 0